KLRAKailera Therapeutics, Inc.

HealthcareUSD
$16.43
On our screens:Stocks with no debt

The financials

Kailera Therapeutics, Inc. by the numbers

Kailera Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$121M−$20Mn/a
Net income−$111M−$18Mn/a
Diluted EPS−$1.09−$17983.00n/a

Biotechnology

The closest names by size in the same industry

Compare peers
CLDX-1.4%
Celldex Therapeutics, Inc.
IRON-3.2%
Disc Medicine, Inc.
TARS-4.0%
Tarsus Pharmaceuticals, Inc.
TRVI-2.6%
Trevi Therapeutics, Inc.
RARE-2.8%
Ultragenyx Pharmaceutical Inc.
VERA-1.7%
Vera Therapeutics, Inc.